

Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Noriho Iida,^{1*} Amiran Dzutsev,^{1,2*} C. Andrew Stewart,^{1*} Loretta Smith,¹ Nicolas Bouladoux,³ Rebecca A. Weingarten,⁴ Daniel A. Molina,⁵ Rosalba Salcedo,¹ Timothy Back,¹ Sarah Cramer,¹ Ren-Ming Dai,^{1,2} Hiu Kiu,¹ Marco Cardone,¹ Shruti Naik,³ Anil K. Patri,⁶ Ena Wang,⁷ Francesco M. Marincola,^{7,8} Karen M. Frank,⁴ Yasmine Belkaid,³ Giorgio Trinchieri,^{1†‡} Romina S. Goldszmid^{1†‡}

The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. Here, we show that disruption of the microbiota impairs the response of subcutaneous tumors to CpG-oligonucleotide immunotherapy and platinum chemotherapy. In antibiotics-treated or germ-free mice, tumor-infiltrating myeloid-derived cells responded poorly to therapy, resulting in lower cytokine production and tumor necrosis after CpG-oligonucleotide treatment and deficient production of reactive oxygen species and cytotoxicity after chemotherapy. Thus, optimal responses to cancer therapy require an intact commensal microbiota that mediates its effects by modulating myeloid-derived cell functions in the tumor microenvironment. These findings underscore the importance of the microbiota in the outcome of disease treatment.

The commensal microbiota influences metabolism, tissue development, inflammation, and immunity (1). The gut microbiota affects inflammation and immunity not only locally at the mucosal level but also systemically (2–5), raising the question of whether the microbiota affects inflammatory processes that contribute to cancer and its therapy. Tumor-associated

inflammatory cells promote cancer cell proliferation and suppress antitumor immunity (6). Anti-cancer treatments alter this microenvironment and may evoke tumor-destructive immune responses (7–9), but whether commensal organisms affect this process is unexplored.

To investigate whether commensal bacteria alter inflammation in the tumor microenviron-


ment, mice received an antibiotic cocktail (ABX) of vancomycin, imipenem, and neomycin in drinking water starting 3 weeks before tumor inoculation and continuing throughout the experiment. To analyze tumors of comparable stages of progression in both wild-type (WT) and genetically altered mice, three C57Bl/6 mouse transplantable tumors were selected based on susceptibility to therapy: EL4 lymphoma, MC38 colon carcinoma, and B16 melanoma. Tumor cells were injected subcutaneously, and mice were analyzed or treated when the tumors reached a diameter of ≥ 4 mm. Gene expression analysis of pretherapy MC38 and EL4 tumors revealed down-regulation of genes related to inflammation, phagocytosis, antigen presentation, and adaptive immune responses in ABX-treated mice but up-regulation of genes related to tissue development, cancer, and metabolism

¹Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, USA. ²Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD 21702, USA. ³Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. ⁴Microbiology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. ⁵Technical Resources International, Inc., Bethesda, MD 20817, USA. ⁶Nanotechnology Characterization Laboratory, Advanced Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, MD 21702, USA. ⁷Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. ⁸Sidra Medical and Research Centre, Doha, Qatar.

*These authors contributed equally to this work.

†These authors contributed equally to this work.

‡Corresponding author. E-mail: trinchig@mail.nih.gov (G.T.); rgoldszmid@mail.nih.gov (R.S.G.)



(fig. S1, A and B). ABX lowered the frequency of monocyte-derived Ly6C⁺MHC class II⁺ cells in EL4 and MC38 tumors and the spleen of MC38 tumor-bearing mice. ABX also decreased Ly6G^{high} neutrophil frequency in MC38 tumors (fig. S2).

To determine whether ABX affect tumor immunotherapy, MC38 and B16 tumor-bearing mice were treated with a combination of intratumoral CpG-oligodeoxynucleotides (ODN), a ligand of Toll-like receptor 9 (TLR9), and inhibitory interleukin-10 (IL-10) receptor antibodies (anti-IL-10R) (10). This immunotherapy retards tumor growth and prolongs survival by rapidly inducing hemorrhagic necrosis dependent on tumor necrosis factor (TNF) production by tumor-associated myeloid cells followed by a CD8 T cell response required for tumor eradication (11). ABX impaired therapy efficacy to retard tumor growth and lengthen survival (Fig. 1, A and B, and fig. S3A). Anti-IL-10R/CpG-ODN treatment induced MC38 tumor necrosis in control mice that was greatly reduced both macroscopically and histologically in ABX-treated animals (Fig. 1, C and D). Similar observations in immunodeficient *Rag1*^{-/-} mice demonstrated that ABX regulate the response to anti-IL-10R/CpG-ODN independently of adaptive immunity (Fig. 1D). However, in *Tnf*^{-/-} mice, anti-IL-10R/CpG-ODN induced minimal necrosis and had no effect on tumor growth in either control or ABX-treated mice (Fig. 1, C and D, and fig. S3B).

ABX significantly impaired CpG-ODN-induced *Tnf* expression and frequencies of TNF-positive leukocytes in MC38 tumors at 3 hours (Fig. 2, A and B). ABX decreased the frequencies of TNF-producing cells and the amount of cytokine per cell in Ly6C⁺MHC-II⁺ monocytes, Ly6C⁺F4/80^{hi} macrophages, CD11c^{hi}MHC-II⁺ dendritic cells (DC), and Ly6C⁺F4/80^{int}MHC-II⁺ monocyte-derived cells (fig. S4, A to C). ABX also decreased CD86 expression and IL-12B production in tumor-associated DC (fig. S4, D and E). After anti-IL-10R/CpG-ODN, tumors from ABX-treated mice also displayed diminished expression of pro-inflammatory *Il1a*, *Il1b*, *Il12b*, and *Cxcl10*, but not of anti-inflammatory *Il10*, *Il1rn*, and *Socs3* or *Nos2* genes (fig. S5). To determine whether the ABX effect was dependent on decreased bacteria load, germ-free (GF) or specific pathogen-free (SPF) mice bearing MC38 tumors received anti-IL-10R/CpG-ODN treatment. Tumors of GF as compared to SPF control mice produced significantly lower amounts of TNF and IL-12B (Fig. 2, C to E). Thus, commensal microbiota primes tumor-associated innate myeloid cells for inflammatory cytokine production in response to anti-IL-10R/CpG-ODN, and ABX or the GF status of the mice attenuates this response and the TNF-dependent early tumor necrosis.

Gavage administration thrice weekly of bacterial lipopolysaccharide (LPS) largely restored *Tnf* expression and frequency of TNF-producing leukocytes in tumors of ABX-treated WT mice but not *Tlr4*^{-/-} mice [lacking the Toll-like receptor 4 (TLR4) receptor for LPS] (Fig. 2F and fig. S6A). Conversely, *Tlr4* deficiency led to lower

induction of *Tnf* and reduced tumor regression after immunotherapy (Fig. 2, F and G), whereas *Tlr2* deficiency had no effect (fig. S6B). Overall, these findings suggest that bacterial products, in part through TLR4 activation, directly or indirectly prime tumor-associated myeloid cells for TLR9-dependent response to CpG-ODN. The ability of oral ABX treatment to reduce gastrointestinal but not skin bacterial load, combined with an absence of bacterial DNA in tumors and the restorative effect of gastrointestinal LPS administration, suggest that intestinal bacteria regulate the inflammatory response in the tumor microenvironment.

To determine how individual bacterial species affect the antitumor response, we correlated fecal microbiota composition with TNF production. Principal-component analysis of natural variation in microbiota composition versus TNF production suggested a codependence (fig. S7). Two experimental microbiota perturbations were used: (i) three-week ABX treatment followed by a 1- to 4-week recovery, and (ii) three-week single-antibiotic treatments. Bacterial abundance was restored to pretreatment levels 1 week after ABX cessation (Fig. 3A); bacterial diversity (fig. S8) and composition gradually increased, although neither reached the pre-ABX condition (Fig. 3, B and C, and figs. S9 and S10). *Tnf* expression did not recover until week 4 post-ABX (Fig. 3D). All the single antibiotics tested increased variability

in *Tnf* expression, whereas only imipenem consistently reduced total bacterial abundance (fig. S11, A to D, and fig. S12). The different perturbations resulted in different bacteria being present. Thus, partially overlapping genera were identified that positively or negatively correlated with *Tnf* expression (figs. S13 and S14A). Among the positive correlates were Gram-negative genera [e.g., *Alistipes* (figs. S13 and S14A)], consistent with a role for TLR4 in priming TNF production. However, Gram-positive genera also showed positive correlation, suggesting that recognition pathways other than TLR4 were also involved. Identification of the same genera in different data sets increased the confidence in the validity of the correlation. Particularly, one genus (*Lactobacillus*) negatively and one (*Ruminococcus*) positively correlated with TNF expression in all three analyses (fig. S13). The *Lactobacillus* genus included *L. murinum*, *L. intestinalis*, and *L. fermentum*, the latter previously identified to have anti-inflammatory effects (12, 13). The *Ruminococcus* genus was represented by a single unclassified operational taxonomic unit (OTU) and the *Alistipes* genus by the single *A. shahii* species. *Lactobacillus* species recovered quickly after ABX withdrawal, whereas recovery of *Ruminococcus* and *Alistipes* species was delayed and coincided with restoration of the TNF response (fig. S14B). Administration of cultured *A. shahii* by gavage to mice preexposed




Fig. 2. Commensal bacteria and TLR4 are necessary for optimal TNF production by tumor myeloid cells after anti-IL-10R/CpG treatment. (A) *Tnf* mRNA (Nanostring nCounter) in MC38 tumors from H₂O- or ABX-treated mice exposed or not to anti-IL-10R/CpG-ODN therapy. (B) TNF-producing MC38 tumor infiltrating CD45⁺ cells in H₂O- or ABX-treated mice. (C to E) *Tnf* mRNA [real-time polymerase chain reaction (RT-PCR)] (C) and percentage TNF- (D) or IL-12p40- (E) producing CD45⁺ cells (flow cytometry) in MC38 tumors from SPF or GF mice. (F) MC38 tumor *Tnf* mRNA in WT mice or in *Tlr4*^{-/-} mice orally gavaged or not with LPS (25 mg per kg of weight, three times per week, 2 weeks before and 1 week after tumor injection). (G) MC38 tumor growth in H₂O- or ABX-treated WT mice or *Tlr4*^{-/-} mice treated or not with anti-IL-10R/CpG-ODN. Data show individual mice [(A) to (F)] or means ± SEM (G). **P* < 0.05, ***P* < 0.01, and ****P* < 0.001.

to ABX reconstituted the ability of tumor-associated myeloid cells to produce TNF (Fig. 3E and fig. S15A). Conversely, administration of *L. fermentum* to intact mice attenuated the response (fig. S15B). These association experiments validate the results of the correlation analysis and confirm the ability of these species to influence the tumor response to CpG-ODN.

To determine whether the microbiota also affects cancer treatments not considered to be directly dependent on inflammation processes, we next examined the response to agents used in human cancer chemotherapy. The platinum compounds oxaliplatin and cisplatin cause tumor cytotoxicity by forming platinum DNA adducts and intrastrand cross-links (14). Reactive oxygen species (ROS) are important for DNA damage and apoptosis in response to platinum compounds (15). Oxaliplatin, unlike cisplatin, also induces immunogenic cell death that drives antitumor T cell immunity (9, 16). Oxaliplatin eradicated most subcutaneous EL4 tumors and prolonged survival in control mice, but ABX-treated animals displayed significantly reduced tumor regression and survival (Fig. 4A

and fig. S16A). GF animals similarly failed to respond to oxaliplatin treatment (fig. S16B). The therapeutic effects of oxaliplatin on a different tumor (MC38) and of cisplatin on EL4 tumors were also significantly reduced in ABX-treated mice (fig. S16, C and D).

The effect of ABX was observed as early as day 2 after treatment with oxaliplatin (Fig. 4A), suggesting suppression of early cytotoxicity rather than of inflammation/immunity after immunogenic cell death. Indeed, ABX attenuated most gene expression changes observed in EL4 tumors 18 hours after oxaliplatin treatment (Fig. 4B). The genes inhibited by ABX were related to monocyte differentiation, activation, and function, whereas the genes that were increased in ABX-treated mice were related to cellular functions such as metabolism, transcription, translation, and DNA replication (fig. S17). Gene expression analysis using the Nanostring nCounter technology confirmed the expression changes of selected genes (fig. S18).

Gene expression analysis revealed that after oxaliplatin treatment the induction of pro-

inflammatory genes was decreased in the absence of microbiota, suggesting that inflammation was important for the antitumor effect of the drug. However, unlike anti-IL-10R/CpG-ODN, oxaliplatin antitumor effects were independent of TNF (fig. S19A). The observation that ABX treatment attenuated the induction of *Nox1* and *Cybb* encoding ROS-generating NADPH (reduced nicotinamide adenine dinucleotide phosphate) oxidase 2 (NOX2) and of the ROS-responsive *Nos2*, *Sod1*, and *Sod2* after oxaliplatin led us to examine oxaliplatin-induced ROS production. Oxaliplatin induced ROS in tumors from control but not ABX-treated mice, as detected in vivo by bioluminescence (Fig. 4C). Induction of ROS was dependent on NOX2 encoded by the *Cybb* gene (Fig. 4C). Because NOX2 is expressed in phagocytic cells (17), we examined ROS production in tumor-infiltrating hematopoietic cells ex vivo. The fluorescence intensity of the ROS probe in tumor-infiltrating CD11b⁺Gr-1^{hi} neutrophils and in F4/80⁺ Gr-1^{int} macrophage-like cells increased after oxaliplatin treatment in control mice, but this response was impaired in ABX-treated or *Cybb*^{-/-} animals (Fig. 4D). ROS inhibition by the antioxidant N-acetyl cysteine (NAC) was previously shown to block oxaliplatin-induced apoptosis of cancer cell lines in vitro and inhibit the effectiveness of oxaliplatin therapy of mouse tumor cell lines in vivo (18, 19). We found that inhibition of ROS by either *Cybb* deficiency or NAC impaired oxaliplatin-induced EL4 tumor regression as early as day 2 and decreased overall survival at an extent comparable to that of ABX (Fig. 4E and fig. S19B). Depletion of myeloid cells by Gr-1 antibody impaired the ability of oxaliplatin to induce tumor regression and to increase survival (Fig. 4F and fig. S19C). These data suggest that the reduced effect of oxaliplatin in ABX-treated or GF mice is partially due to reduced myeloid-cell ROS production. To investigate whether gut commensals prime these cells by release of TLR agonists, we studied *Thr4*^{-/-} and *Myd88*^{-/-} mice. (*Myd88* is the adaptor protein that signals downstream of IL-1 family receptors and most TLRs.) *Myd88*, but not *Thr4*, deficiency impaired the early antitumor effect of oxaliplatin, although *Thr4* deficiency had a partial effect on long-term tumor growth and survival (fig. S19D). *Il1r* or *Il18r* deficiency did not impair the response (fig. S19D), suggesting that the commensal effect was related to microbial product sensing.

The levels of tumor DNA-bound platinum were similar in control and ABX-treated mice, although tumors from ABX-treated mice showed reduced DNA damage (fig. S20). These data suggest that ABX prevent oxaliplatin-induced DNA damage and apoptosis after DNA adduct formation in part by decreasing ROS production (15, 18, 19). In ABX-treated mice, the decreased induction of the DNA damage response gene *Atr* and of the p53 downstream genes *Bax*, *Fas*, *Cdkn1a*, and *Rb1* is compatible with reduced tumor DNA damage and p53-dependent activation of apoptosis. Although tumor-cell-produced ROS were previously reported to be required for the




Fig. 3. Commensal microbiota composition correlates with tumor TNF response. (A and B) MC38 tumors were subcutaneously implanted 1, 2, or 4 weeks after the cessation of a 3-week ABX treatment. Control mice continuously drinking H₂O or ABX were included. (A) Eubacteria 16S ribosomal RNA gene copy number in feces was determined by RT-PCR. (B) 16S-sequence frequencies were analyzed by pyrosequencing in fecal microbiota. Data are shown as heat map of OTUs (97% similarity) normalized to copy number of 16S per gram of feces (OTUs represented by <0.1% of total reads were removed from the analysis). (C) Principal-component analysis of unweighted Unifrac distances. (D) Tumor *Tnf* mRNA expression 3 hours after anti-IL-10R/CpG-ODN treatment was determined by RT-PCR. (E) Control H₂O-drinking mice or 1 week after cessation of ABX treatment were exposed to anti-IL-10R/CpG-ODN therapy. A group of ABX pre-exposed mice was subjected to oral gavage with *A. shahii*. Mice were killed 3 hours after CpG-ODN treatment, and intracellular TNF was measured in the indicated tumor-associated myeloid cell subsets. Data show individual mice and means ± SEM from one representative experiment out of two performed [(A) and (D)] or combined data from two experiments (E).




Fig. 4. Commensal bacteria control oxaliplatin therapy response by modulating ROS production. (A) Subcutaneous EL4 tumor-bearing H₂O- or ABX-treated mice were treated with oxaliplatin (10 mg per kg of weight); tumor growth (top) and survival (bottom) are shown. (B) Global gene expression ($q < 0.1$, >2 -fold change compared to time 0, two-way analysis of variance analysis) in tumors from H₂O- and ABX-treated mice before (0 hours) and after (6 and 18 hours) oxaliplatin treatment. (C and D) ROS production 24 hours after oxaliplatin injection in subcutaneous EL4 tumors from H₂O- or ABX-treated WT mice and *Cybb*^{-/-} mice was measured in vivo by bioluminescence (probe L-012) [inset in (C) shows a representative mouse with tumor area marked in red] and ex vivo in tumor-infiltrating cells (D, fluorescent probe, flow cytometry). (E and F) EL4-bearing WT and *Cybb*^{-/-} mice (E) and Gr-1 antibody- or immunoglobulin G isotype-treated mice (F) were treated with oxaliplatin. (A), (C), and (E) show data combined from several independent experiments; (D) and (F) show a representative experiment out of two.

cytotoxic effect of platinum compounds in vitro, our data indicate that the ROS required for oxaliplatin genotoxicity in vivo are mostly derived from tumor-associated inflammatory cells. Because ABX treatment affected tumor cytotoxicity shortly after chemotherapy, and this effect was observed using both oxaliplatin and its relative cisplatin that is unable to trigger immunogenic cell death, the data suggest that commensal bacteria modulate the genotoxicity of platinum compounds independently of immunity elicited by immunogenic cell death. However, DC activation and adaptive antitumor immune responses after oxaliplatin

may also require a commensal-dependent inflammatory response.

Besides platinum complexes, drugs such as anthracyclines, alkylating agents, podophyllotoxins, and camptothecine induce ROS as part of their anticancer activity and may be similarly regulated (15, 20–22). Mechanisms by which the gut microbiota affects the systemic inflammatory tone are only now being uncovered (23, 24). In a different setting, total body irradiation was shown to increase the efficacy of adoptively transferred tumor-specific CD8⁺ T cells in part by inducing microbial translocation (25). Our study indicates

that commensal bacteria differentially affect the type of inflammatory tone required for response to different therapeutic protocols and highlights the potential to improve cancer treatment by manipulating human gut microbiota.

References and Notes

- Y. K. Lee, S. K. Mazmanian, *Science* **330**, 1768–1773 (2010).
- J. C. Clemente, L. K. Ursell, L. W. Parfrey, R. Knight, *Cell* **148**, 1258–1270 (2012).
- J. P. McAleer, J. K. Kolls, *Immunity* **37**, 10–12 (2012).
- M. C. Abt et al., *Immunity* **37**, 158–170 (2012).
- T. Ichinohe et al., *Proc. Natl. Acad. Sci. U.S.A.* **108**, 5354–5359 (2011).
- S. I. Grivennikov, F. R. Greten, M. Karin, *Cell* **140**, 883–899 (2010).
- Y. Shirota, H. Shirota, D. M. Klinman, *J. Immunol.* **188**, 1592–1599 (2012).
- L. Zitvogel, O. Kepp, G. Kroemer, *Cell* **140**, 798–804 (2010).
- L. Apetoh et al., *Nat. Med.* **13**, 1050–1059 (2007).
- A. P. Vicari et al., *J. Exp. Med.* **196**, 541–549 (2002).
- C. Guiducci, A. P. Vicari, S. Sangaletti, G. Trinchieri, M. P. Colombo, *Cancer Res.* **65**, 3437–3446 (2005).
- R. R. Jenq et al., *J. Exp. Med.* **209**, 903–911 (2012).
- L. Peran et al., *Br. J. Nutr.* **97**, 96–103 (2007).
- Z. H. Siddik, *Oncogene* **22**, 7265–7279 (2003).
- T. Ozben, *J. Pharm. Sci.* **96**, 2181–2196 (2007).
- F. Ghiringhelli et al., *Nat. Med.* **15**, 1170–1178 (2009).
- G. R. Drummond, S. Selemidis, K. K. Griendling, C. G. Sobey, *Nat. Rev. Drug Discov.* **10**, 453–471 (2011).
- S. Kim, T. J. Lee, J. W. Park, T. K. Kwon, *J. Cell. Biochem.* **105**, 971–979 (2008).
- A. Laurent et al., *Cancer Res.* **65**, 948–956 (2005).
- K. A. Conklin, *Integr. Cancer Ther.* **3**, 294–300 (2004).
- J. Fang, H. Nakamura, A. K. Iyer, *J. Drug Target.* **15**, 475–486 (2007).
- S. Simizu, M. Takada, K. Umezawa, M. Imoto, *J. Biol. Chem.* **273**, 26900–26907 (1998).
- S. C. Ganai et al., *Immunity* **37**, 171–186 (2012).
- Y. Huang et al., *Genes Immun.* **13**, 311–320 (2012).
- C. M. Paulos et al., *J. Clin. Invest.* **117**, 2197–2204 (2007).

Acknowledgments: We greatly appreciate the support of D. Trageser-Cessler and A. Cesar in the NIAID germ-free facility; H. Zhou in the NIH Center for Human Immunology; T. Plona and K. Pike in the Laboratory of Molecular Technology, Leidos Biomedical Research, Inc.; and R. Winkler-Pickett, M. Karwan, and D. Zhao in the Cancer and Inflammation Program, CCR/NCI. We thank D. Klinman and A. Hurwitz for advice and R. Germain for critically reviewing the manuscript. The data presented in this manuscript are tabulated in the main paper and in the supplementary materials. This research was supported by the Intramural Research Program of the NIH (NCI, Center for Cancer Research, and NIAID) and the Japanese Society for Promotion of Science (JSPS) Research Fellowship for Japanese Biomedical and Behavioral Researchers at NIH. The 16S sequences were deposited in the Sequence Read Archive (SRA) under accession PRJNA221649. Array data were deposited at the Gene Expression Omnibus (GEO) with accession no. GSE51414.

Supplementary Materials

www.sciencemag.org/content/342/6161/967/suppl/DC1
Materials and Methods
Figs. S1 to S20
References (26–36)

15 May 2013; accepted 15 October 2013
10.1126/science.1240527



EXTENDED PDF FORMAT
SPONSORED BY



Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment

Noriho Iida, Amiran Dzutsev, C. Andrew Stewart, Loretta Smith, Nicolas Bouladoux, Rebecca A. Weingarten, Daniel A. Molina, Rosalba Salcedo, Timothy Back, Sarah Cramer, Ren-Ming Dai, Hiu Kiu, Marco Cardone, Shruti Naik, Anil K. Patri, Ena Wang, Francesco M. Marincola, Karen M. Frank, Yasmine Belkaid, Giorgio Trinchieri and Romina S. Goldszmid (November 21, 2013) *Science* **342** (6161), 967-970. [doi: 10.1126/science.1240527]

Editor's Summary

The Microbiota Makes for Good Therapy

The gut microbiota has been implicated in the development of some cancers, such as colorectal cancer, but—given the important role our intestinal habitants play in metabolism—they may also modulate the efficacy of certain cancer therapeutics. **Iida *et al.*** (p. 967) evaluated the impact of the microbiota on the efficacy of an immunotherapy [CpG (the cytosine, guanosine, phosphodiester link) oligonucleotides] and oxaliplatin, a platinum compound used as a chemotherapeutic. Both therapies were reduced in efficacy in tumor-bearing mice that lacked microbiota, with the microbiota important for activating the innate immune response against the tumors. **Viaud *et al.*** (p. 971) found a similar effect of the microbiota on tumor-bearing mice treated with cyclophosphamide, but in this case it appeared that the microbiota promoted an adaptive immune response against the tumors.

This copy is for your personal, non-commercial use only.

Article Tools

Visit the online version of this article to access the personalization and article tools:

<http://science.sciencemag.org/content/342/6161/967>

Permissions

Obtain information about reproducing this article:

<http://www.sciencemag.org/about/permissions.dtl>

Science (print ISSN 0036-8075; online ISSN 1095-9203) is published weekly, except the last week in December, by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. Copyright 2016 by the American Association for the Advancement of Science; all rights reserved. The title *Science* is a registered trademark of AAAS.